Reasons for hope: The drugs, tests and tactics that may conquer coronavirus

Times Now | April 14, 2020

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinical trials. Even moderately effective therapies or combinations could dramatically reduce the crushing demand on hospitals and intensive care units, changing the nature of the risk the new pathogen represents to populations and healthcare systems. New drugs, together with new diagnostics, antibody tests, patient- and contact-tracing technologies, disease surveillance and other early-warning tools, mean the anticipated next "wave" of the global pandemic does not have to be nearly as bad the first.

Spotlight

Autism is a growing concern not only for parents and children but healthcare providers as well as researchers and public health officials. The latest numbers from the Centers for Disease Control and Prevention show that the prevalence of autism has increased to 1 in 59 children, a jump from the previous number of 1 in 68 children. It's more common in boys than in girls, but not by much, and some experts believe that is a problem of bias in diagnosing girls on the spectrum who do not present the same way as boys.

Spotlight

Autism is a growing concern not only for parents and children but healthcare providers as well as researchers and public health officials. The latest numbers from the Centers for Disease Control and Prevention show that the prevalence of autism has increased to 1 in 59 children, a jump from the previous number of 1 in 68 children. It's more common in boys than in girls, but not by much, and some experts believe that is a problem of bias in diagnosing girls on the spectrum who do not present the same way as boys.

Related News

PHARMA TECH

BenchSci Named a Deloitte Technology Fast 50™ Company as Impact on Drug Discovery Grows

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “This recognition is a confirmation of our groundbreaking work to bring novel medicine to patients faster. Our machine learning technology decodes and organizes the world’s most comprehensive biomedical dataset like a Ph.D. scientist. As a result, we eliminate experiments that delay progress and drain research budgets in the world’s largest pharmaceutical companies. This award reflects the value we’re bringing not only to our customers’ research productivity but to all of us who benefit from healthcare innovation.” Liran Belenzon, CEO, BenchSci To qualify for the Tech Fast 50™, companies must have been in business for at least four years, have revenues of at least $5 million, be headquartered in Canada, own proprietary technology, conduct research and development activities in Canada, and invest a minimum of five percent of gross revenues in Research and Development. Founded in 2015, BenchSci has rapidly grown its customer base since launching commercially in 2017. In addition to powering research in over 4,300 academic labs, BenchSci is an indispensable tool for preclinical R&D in 15 of the top 20 global pharmaceutical companies. A remote-first company with headquarters in Toronto, BenchSci is a leader in biomedical machine learning and continuously invests in researching and developing AI-powered tools to help scientists run more successful experiments. “I am thankful for the innovation and commitment of our team members that enable scientists to accelerate drug discovery,” continues Belenzon. “We are honored with the trust our customers place in us as we build the next generation of products that will continue to transform R&D.” About the Deloitte Technology Fast 50™ program The Deloitte Technology Fast 50 program is Canada’s pre-eminent technology awards program. Celebrating business growth, innovation and entrepreneurship, the program features distinct categories, including the Technology Fast 50 ranking, Enterprise Fast 15, Clean Technology, and Companies-to-Watch. The program also recognizes companies within the North American Technology Fast 500 ranking, identifying technology companies in the United States and Canada. The 2021 program sponsors include Deloitte, RBC, EDC, Miller Thomson, Clarity Recruitment, and Lafond. About BenchSci BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, our platform accelerates science at 15 top-20 pharmaceutical companies and over 4,300 leading research centers worldwide. We’re a Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor.

Read More

PRACTICE MANAGEMENT

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

Ascentage Pharma | January 14, 2021

Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&D outline. Dr. Yang conveyed a generally welcomed introduction on the organization's item pipeline and clinical advancement progress. As a worldwide pioneer in the improvement of therapeutics focusing on the protein-to-protein collaborations, Ascentage Pharma has assembled a pipeline of exceptionally serious resources, a considerable lot of which with first-in-class or top tier possibilities (Table 1). Until now, Ascentage Pharma has gotten 33 clinical preliminary endorsements or clearances, with more than 40 clinical examinations on-circumventing the world. As a main biopharmaceutical organization zeroing in on the improvement of apoptosis-focusing on treatments, Ascentage Pharma has assembled a rich and strong pipeline, with five medication applicants focusing on the three key apoptotic pathways - Bcl-2, IAP, and MDM2-p53, and has progressed all these five competitors into clinical turn of events. APG-2575, the organization's orally-managed novel little atom Bcl-2 inhibitor, pulled in a lot of interest from the business and examination local area, as it is one of only a handful few Bcl-2 particular inhibitors, after venetoclax, that have entered clinical turn of events. It is additionally the principal China-created Bcl-2 inhibitor entering clinical turn of events. In December 2020, Ascentage Pharma delivered refreshed outcomes from the clinical investigations of APG-2575 in the therapy of backslid/obstinate ongoing lymphocytic lymphoma (r/r CLL) which have selected more than 30 patients. Starter results show that an exceptionally reassuring target reaction rate (ORR) of 70% has been reached in evaluable patients. At this meeting, Dr. Yang shared extra subtleties on these outcomes.

Read More

PHARMACY MARKET

Prescryptive Health Launches COVID-19 Treatment Solution for Pharmacists

Prescryptive Health | September 29, 2021

Healthcare technology company Prescryptive Health today announced a turn-key solution for pharmacists to treat COVID-19 through monoclonal antibody administration. This new program builds on the company's work with community pharmacists on COVID-19 testing and vaccine services and supports the National Community Pharmacists Association's effort to prepare pharmacists to provide this treatment. As in all our COVID-19 solutions, we are empowering pharmacists to help end this pandemic, through identifying, reporting, preventing, and now treating this virus, More than 90% of Americans live within five miles of a pharmacy, and pharmacists have proven again and again how essential they are in their communities. - Chris Blackley, Prescryptive Health's CEO The solution is truly turn-key, allowing pharmacists to get trained and provide COVID-19 treatment to their communities quickly. As this public health crisis continues, pharmacists can support their communities in new ways through this program. - Michele Belcher, incoming NCPA president and pharmacist at Grants Pass Pharmacy in Oregon Prescryptive Health's robust, one-hour ACPE-accredited continuing education training for COVID-19 monoclonal antibody treatment is free for pharmacists nationwide. NCPA supports the continuing education program built by Prescryptive. In combination with the NCPA resources, pharmacists have the tools necessary to prepare administering this clinical service. The innovative program also includes a clinical protocol developed by subject matter experts and leading regulators; policies and procedures to help pharmacies operationalize the service; guidance on accessing inventory as it becomes available; and billing services, through Prescryptive's partnership with AssureCare®. This program will debut in Oregon, with additional locations added across the nation in the coming weeks. Belcher and Paige Clark, VP of Programs and Policy at Prescryptive Health, will present at the NCPA conference in October on the COVID-19 treatment program, showing how pharmacists are playing a crucial role for public health in their communities. About Prescryptive Health Prescryptive Health is a healthcare technology company delivering solutions that empower consumers. Prescryptive's secure, mobile-first products connect consumers, pharmacists, and employers, ultimately providing people with the information they need to make informed decisions and take control of their health.

Read More